199 related articles for article (PubMed ID: 29765548)
1. Transformation of mouse T cells requires MYC and AKT activity in conjunction with inhibition of intrinsic apoptosis.
Högstrand K; Darmanin S; Forshell TP; Grandien A
Oncotarget; 2018 Apr; 9(30):21396-21410. PubMed ID: 29765548
[TBL] [Abstract][Full Text] [Related]
2. MYC-driven malignant transformation of mature murine B cells requires inhibition of both intrinsic apoptosis and p53 activity.
Högstrand K; Grandien A
Eur J Immunol; 2019 Mar; 49(3):375-385. PubMed ID: 30281155
[TBL] [Abstract][Full Text] [Related]
3. Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.
Tan Y; Sementino E; Pei J; Kadariya Y; Ito TK; Testa JR
Cancer Biol Ther; 2015; 16(4):580-8. PubMed ID: 25793663
[TBL] [Abstract][Full Text] [Related]
4. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.
Han SS; Yun H; Son DJ; Tompkins VS; Peng L; Chung ST; Kim JS; Park ES; Janz S
Mol Cancer; 2010 Apr; 9():97. PubMed ID: 20433747
[TBL] [Abstract][Full Text] [Related]
5. Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways.
Xin B; Yamamoto M; Fujii K; Ooshio T; Chen X; Okada Y; Watanabe K; Miyokawa N; Furukawa H; Nishikawa Y
Oncogene; 2017 Sep; 36(36):5087-5097. PubMed ID: 28481866
[TBL] [Abstract][Full Text] [Related]
6. AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.
Devlin JR; Hannan KM; Ng PY; Bywater MJ; Shortt J; Cullinane C; McArthur GA; Johnstone RW; Hannan RD; Pearson RB
FEBS J; 2013 Nov; 280(21):5307-16. PubMed ID: 23331925
[TBL] [Abstract][Full Text] [Related]
7. c-MYC overexpression overrides TAK1 dependency in efficient tumorigenicity of AKT-transformed cells.
Qu Y; Zhang L; Ma A; Zhang F; Li J; Xu D; Yang Z; Qin W; Liu Y
Cancer Lett; 2013 Aug; 336(2):290-8. PubMed ID: 23523871
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 and c-Myc co-operate in the Epstein-Barr virus-immortalized human B-cell line GM607 but do not confer tumorigenicity.
Tomlin JL; Guinn BA; Penn LZ; Berinstein NL
Leuk Lymphoma; 2005 Apr; 46(4):581-92. PubMed ID: 16019487
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia.
Högstrand K; Hejll E; Sander B; Rozell B; Larsson LG; Grandien A
PLoS One; 2012; 7(2):e31366. PubMed ID: 22393362
[TBL] [Abstract][Full Text] [Related]
10. The E-Id protein axis modulates the activities of the PI3K-AKT-mTORC1-Hif1a and c-myc/p19Arf pathways to suppress innate variant TFH cell development, thymocyte expansion, and lymphomagenesis.
Miyazaki M; Miyazaki K; Chen S; Chandra V; Wagatsuma K; Agata Y; Rodewald HR; Saito R; Chang AN; Varki N; Kawamoto H; Murre C
Genes Dev; 2015 Feb; 29(4):409-25. PubMed ID: 25691468
[TBL] [Abstract][Full Text] [Related]
11. c-Myc dysregulation is a co-transforming event for nuclear factor-κB activated B cells.
David A; Arnaud N; Fradet M; Lascaux H; Ouk-Martin C; Gachard N; Zimber-Strobl U; Feuillard J; Faumont N
Haematologica; 2017 May; 102(5):883-894. PubMed ID: 28232371
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-β directly induces p53-up-regulated modulator of apoptosis (PUMA) during the rapid induction of apoptosis in myc-driven B-cell lymphomas.
Spender LC; Carter MJ; O'Brien DI; Clark LJ; Yu J; Michalak EM; Happo L; Cragg MS; Inman GJ
J Biol Chem; 2013 Feb; 288(7):5198-209. PubMed ID: 23243310
[TBL] [Abstract][Full Text] [Related]
13. p53, c-myc p62 and proliferating cell nuclear antigen (PCNA) expression in non-Hodgkin's lymphomas.
Korkolopoulou P; Oates J; Kittas C; Crocker J
J Clin Pathol; 1994 Jan; 47(1):9-14. PubMed ID: 7907610
[TBL] [Abstract][Full Text] [Related]
14. Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.
Reynolds C; Roderick JE; LaBelle JL; Bird G; Mathieu R; Bodaar K; Colon D; Pyati U; Stevenson KE; Qi J; Harris M; Silverman LB; Sallan SE; Bradner JE; Neuberg DS; Look AT; Walensky LD; Kelliher MA; Gutierrez A
Leukemia; 2014 Sep; 28(9):1819-27. PubMed ID: 24552990
[TBL] [Abstract][Full Text] [Related]
15. 13-methyltetradecanoic acid exhibits anti-tumor activity on T-cell lymphomas in vitro and in vivo by down-regulating p-AKT and activating caspase-3.
Cai Q; Huang H; Qian D; Chen K; Luo J; Tian Y; Lin T; Lin T
PLoS One; 2013; 8(6):e65308. PubMed ID: 23762338
[TBL] [Abstract][Full Text] [Related]
16. MYC rearrangements in histologically progressed follicular lymphomas.
Yano T; Jaffe ES; Longo DL; Raffeld M
Blood; 1992 Aug; 80(3):758-67. PubMed ID: 1638027
[TBL] [Abstract][Full Text] [Related]
17. c-Myc and cyclin D3 (CcnD3) genes are independent targets for glucocorticoid inhibition of lymphoid cell proliferation.
Rhee K; Bresnahan W; Hirai A; Hirai M; Thompson EA
Cancer Res; 1995 Sep; 55(18):4188-95. PubMed ID: 7664296
[TBL] [Abstract][Full Text] [Related]
18. T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma.
Hilmenyuk T; Ruckstuhl CA; Hayoz M; Berchtold C; Nuoffer JM; Solanki S; Keun HC; Beavis PA; Riether C; Ochsenbein AF
Oncoimmunology; 2017; 7(1):e1365997. PubMed ID: 29296517
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.
Yan ZX; Wu LL; Xue K; Zhang QL; Guo Y; Romero M; Leboeuf C; Janin A; Chen SJ; Wang L; Zhao WL
Leukemia; 2014 Apr; 28(4):880-7. PubMed ID: 24104394
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis and proliferative activity of non-Hodgkin's lymphomas: comparison with expression of bcl-2, p53 and c-myc proteins.
Takano Y; Saegusa M; Ikenaga M; Okayasu I
Pathol Int; 1997; 47(2-3):90-4. PubMed ID: 9088026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
